Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells ...

Immune checkpoint inhibitors have revolutionized cancer treatment, yet many tumours develop strategies to evade or suppress immune responses, limiting long-term efficacy. This webcast will examine how ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

Scientists at MD Anderson Cancer Center discovered that the mitochondrial enzyme GFER promotes an immunosuppressive tumor environment in pancreatic cancer.

Explore how aggressive breast cancer evades immune defences and discover potential treatment strategies with our latest ...

Distant metastasis and recurrence remain major obstacles limiting the long-term efficacy of immunotherapy for solid tumors, particularly in highly aggressive cancers, such as malignant melanoma.